Pricing & Access· June 24, 2026 · 25 min read
Topic
Diabetes and Obesity
Metabolic drug access, GLP-1 and GIP/GLP-1 competition, obesity coverage, diabetes formularies, and payer restrictions.
Evidence· June 19, 2026 · 14 min read
Insulins in FAERS: 454,039 adverse-event reports by the numbers
Evidence· June 15, 2026 · 11 min read
SGLT2 inhibitors in FAERS: 154,476 adverse-event reports by the numbers
Evidence· June 14, 2026 · 14 min read
GLP-1 receptor agonists in FAERS: adverse-event reporting by the numbers
Pipeline· June 12, 2026 · 9 min read
Retatrutide Phase 3: -28.3% body weight, 45% lose ≥30%, new UTI signal at ADA 2026
By Ran Chen#GLP-1#GIP/GLP-1#Clinical Evidence
Pricing & Access· June 9, 2026 · 10 min read
Awiqli coverage guide: insulin icodec access, PA criteria, and Part D pricing
Generics· June 9, 2026 · 9 min read
Dapagliflozin generic entry: Farxiga ANDA playbook and formulary impact
By Ran Chen#SGLT2 Inhibitor#ANDA Approval#Orange Book
Biosimilars· June 7, 2026 · 8 min read
Langlara insulin glargine biosimilar: interchangeable Lantus, formulary, and switching
Pricing & Access· June 6, 2026 · 14 min read
GLP-1 weight loss vs diabetes insurance coverage: how the indication changes everything
By Ran Chen#GLP-1#Prior Authorization#Weight Loss
Pricing & Access· June 6, 2026 · 12 min read
Medicare Part D GLP-1 coverage 2026: Bridge program, $2,100 cap, and indications
By Ran Chen#GLP-1#Medicare Part D#Prior Authorization